All articles by Abigail Beaney

Abigail Beaney

Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including neurodegenerative, infectious and metabolic diseases. Abigail holds a first-class BA (Hons) degree in Journalism from the University of Central Lancashire in the United Kingdom. She has also obtained the National Qualification in Journalism through the UK's media industry body, the National Council for the Training of Journalists. Contact Abigail

Smarter data, faster decisions: How biotech funding pressures are reshaping clinical development

As the biotech sector emerges from a challenging funding cycle, its effects continue to shape how companies design trials, generate…
AAIC26: Biogen stock drops after unveiling tau-targeting ASO data

Biogen’s stock has dropped after it released mixed data on its tau-targeting investigational antisense oligonucleotide (ASO), compounding a previous announcement…
FDA finalises psychedelic clinical trial guidance

The US Food and Drug Administration (FDA) has finalised its formal guidance for clinical trials involving psychedelic drugs. The FDA…
Alkermes releases nine-month data as OX2R race heats up

Alkermes’ oral, selective orexin 2 receptor (OX2R) agonist has shown continued benefit nine months after the start of treatment in…
GSK’s partner Hansoh Pharma succeeds in Chinese Phase III SCLC ADC trial

GSK’s bet on Hansoh Pharmaceutical’s antibody-drug conjugate (ADC) seems to be paying off as the drug met all its endpoints…

Roche culls development of two Huntington’s disease programmes

Roche has stopped development of two of its Huntington’s disease candidates after one failed to show benefit in a Phase…
AstraZeneca and Ionis’ stocks drop significantly on Wainua ATTR-CM trial failure

Both AstraZeneca and Ionis’ stocks took a hit at market open on 9 July after the companies announced that a…
Satellos’ oral DMD drug improves arm movement after six months in Phase II

Satellos Bioscience’s oral Duchenne muscular dystrophy (DMD) drug has increased upper limb activity in four patients in a Phase II…
Turn Therapeutics’ stock jumps on AD data and trial expansion

Turn Therapeutics’ stock has jumped by 26% after its atopic dermatitis (AD) candidate boasted clinically meaningful efficacy in a Phase…
Compass’ psilocybin shows six-month durability in Phase III trial

Compass Pathways’ psilocybin-based therapy has continued to show benefit after six months in a Phase III trial in treatment-resistant depression…